Table 10.
Baseline Characteristics of the Second Study Population
| Characteristic | Healthy Control (n=15) | Stable CAD (n=34) | P Value |
|---|---|---|---|
| Age, y | 66.3±2.44 | 62.2±1.72 | 0.194 |
| Male | 10 (66.7) | 4 (11.8) | <0.001 |
| Cardiovascular risk factors, no. (%) | |||
| Arterial hypertension | 9 (73.3) | 23 (72.7) | 1 |
| Hyperlipoproteinemia | 4 (28.6) | 24 (72.7) | 0.005 |
| Diabetes | 0 | 0 | |
| Family history of CAD | 1 (7.1) | 7 (21.2) | 0.405 |
| Smoking | 2(14.3) | 14 (42.4) | 0.0603 |
| Body mass index, kg/m2 | 28.1±2.1 | 27.7±0.6 | 0.848 |
| Laboratory parameters | |||
| Cholesterol, mg/dL | 191.6±8.8 | 173.6±8.32 | 0.201 |
| LDL cholesterol, mg/dL | 114.5±7.78 | 106.9±6.23 | 0.484 |
| HDL cholesterol, mg/dL | 58.5±4.41 | 44.6±1.77 | 0.001 |
| Triglycerides, mg/dL | 120.6±13.9 | 154.4±18.1 | 0.247 |
| Serum creatinine, mg/dL | 0.86±0.25 | 1.0±0.24 | 0.062 |
| Leucocytes, 109/L | 6.9±0.45 | 7.8±0.44 | 0.219 |
| C‐reactive protein, mg/L | 3.73±0.9 | 4.6±1.8 | 0.759 |
| Medical history, no. (%) | |||
| Previous MI (6 months) | 0 | 18 (52.9) | <0.001 |
| Previous PCI | 0 | 29 (85.3) | <0.001 |
| Left ventricular ejection fraction, % | 58.8±2.5 | 53.64±2.1 | 0.150 |
| Medication on admission, no. (%) | |||
| ACE inhibitors | 5 (33.3) | 29 (85.3) | <0.001 |
| Angiotensin receptor blockers | 6 (40) | 5 (14.7) | 0.069 |
| Calcium channel blockers | 5 (33.3) | 2 (5.9) | 0.022 |
| Diuretics | 11 (73.3) | 11 (32.4) | 0.012 |
| Statins | 5 (33.3) | 33 (97.1) | <0.001 |
| Nitrates | 0 | 2 (5.9) | 1 |
| Aspirin | 1 (6.7) | 34 (100) | <0.001 |
| Clopidogrel | 0 | 10 (29.4) | 0.021 |
ACE indicates angiotensin‐converting enzyme; CAD, coronary artery disease; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; MI, myocardial infarction; MmiR, microRNA in circulating microvesicles; PCI, percutaneous coronary intervention.